Eli Lilly disrupts weight-loss market with new telehealth service

  • WeightWatchers stock drops 12% after Eli Lilly launches DTC weight-loss drug service
  • Eli Lilly offers telehealth prescriptions and direct home delivery of anti-obesity drug Zepbound
  • WW International has been expanding into telehealth
  • LillyDirect likely to have an advantage while supply of weight-loss drugs is scarce
  • Shares of other telehealth companies also affected

Shares of WW International, also known as WeightWatchers, fell 12% after Eli Lilly introduced a new online service offering telehealth prescriptions and direct home delivery of its anti-obesity drug Zepbound. This move comes as WW International has been expanding into telehealth, acquiring telehealth firm Sequence last year. Analysts predict that Lilly’s telehealth platform, LillyDirect, will have an advantage over competitors due to the scarcity of weight-loss drugs. However, once production increases, the winners and losers in this space will be determined by who can provide the best service. The launch of LillyDirect also impacted the shares of other telehealth companies, including Hims & Hers Health and LifeMD.

Public Companies: WW International (WW), Eli Lilly (LLY), Hims & Hers Health (Unknown), LifeMD (Unknown)
Private Companies:
Key People:

Track all markets on TradingView

Factuality Level: 7
Justification: The article provides information about the drop in shares of WW International and other telehealth companies after Eli Lilly launched a new online service for its anti-obesity drug. The information seems to be based on factual events and statements from analysts. However, there is no mention of any potential bias or conflicting perspectives, and the article lacks in-depth analysis or additional sources to support the claims made.

Noise Level: 3
Justification: The article provides relevant information about the impact of Eli Lilly’s new online service on WW International’s stock. It mentions the stock’s decline, the reason behind it, and the potential advantage of Lilly’s telehealth platform. However, it lacks in-depth analysis, evidence, and actionable insights. It also briefly mentions the impact on other telehealth companies’ shares without providing further details or context.

Financial Relevance: Yes
Financial Markets Impacted: Shares of WW International, Hims & Hers Health, and LifeMD

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article discusses the impact of a new telehealth service offered by Eli Lilly on the stock prices of WW International, Hims & Hers Health, and LifeMD. There is no mention of any extreme event.

Reported publicly: www.marketwatch.com